Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 14/20 | 0.76 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.48 |
| ▸ | GSK3A | P49840 | 1/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13721805 | 0.92 | GSK3B (0.64) | GSK3BCYP1A2CYP2D6CSNK1A1GSK3A | |
| SCHEMBL13722148 | 0.92 | GSK3B (0.68) | GSK3B | |
| SCHEMBL13722185 | 0.91 | GSK3B (0.62) | GSK3BCYP2D6 | |
| SCHEMBL13721909 | 0.90 | GSK3B (0.70) | GSK3B | |
| SCHEMBL13722172 | 0.90 | GSK3B (0.61) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL13721987 | 0.90 | GSK3B (0.61) | GSK3B | |
| SCHEMBL4031690 | 0.90 | GSK3B (0.75) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL4026310 | 0.89 | GSK3B (0.77) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL13722101 | 0.88 | GSK3B (0.70) | GSK3BCYP2D6 | |
| SCHEMBL13722200 | 0.88 | GSK3B (0.59) | GSK3BCYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572793-B2 | 3-Substituted-4-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-08-11 | — | — | US | claimed |
| EP-1427720-B1 | 3-SUBSTITUTED-4-PYRIMIDONE DERIVATIVES | MITSUBISHI TANABE PHARMA CORP (JP) | 2009-03-04 | — | — | EP | claimed |
| EP-1427709-B1 | 3-SUBSTITUTED-4-PYRIMIDONE DERIVATIVES | MITSUBISHI PHARMA CORP (JP) | 2005-12-14 | — | — | EP | claimed |
| US-20050130967-A1 | 3-Substituted-4-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2005-06-16 | — | — | US | claimed |
| US-7572793-B2 | 3-Substituted-4-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-08-11 | — | — | US | disclosed |
| US-7572793-B2 | 3-Substituted-4-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-08-11 | — | — | US | disclosed |
| US-7572793-B2 | 3-Substituted-4-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-08-11 | — | — | US | disclosed |
| US-20050130967-A1 | 3-Substituted-4-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130967-A1 | 3-Substituted-4-pyrimidone derivatives | TTBK1, CDK1, MAPT | GSK3B 172/4885CYP1A2 2399/4885CYP2D6 2047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.